Prof. Benkang Shi: Building Academic Synergy Across the Yellow River Region to Advance High-Quality Development of Urology in Shandong

Prof. Benkang Shi: Building Academic Synergy Across the Yellow River Region to Advance High-Quality Development of Urology in Shandong

The 3rd Yellow River Urology Congress and the 31st Academic Conference on Urology of the Shandong Medical Association were recently held, bringing together leading urologists from across China to discuss the latest advances in the field, innovations in clinical practice, talent development, and regional collaboration.
CUDA 2026 | Prof. Xiaoying Li: From Technological Innovation to MDT Collaboration—Redefining the Landscape of Urologic Oncology

CUDA 2026 | Prof. Xiaoying Li: From Technological Innovation to MDT Collaboration—Redefining the Landscape of Urologic Oncology

The 2026 Annual Meeting of the Chinese Urological Association (CUDA) was held in Zhengzhou from June 11–14, bringing together leading experts in urology and related disciplines under the theme "Unity, Collaboration, Innovation, and Development." The meeting focused on advancing high-quality clinical research, technological innovation, multidisciplinary collaboration (MDT), and regional cooperation, while promoting the continued development of comprehensive care for urologic diseases.
BOC 2026 | Prof. Pei Dong: Kidney Cancer Enters the Era of Long-Term Survival, with New Advances in Adjuvant Therapy and Comprehensive Disease Management

BOC 2026 | Prof. Pei Dong: Kidney Cancer Enters the Era of Long-Term Survival, with New Advances in Adjuvant Therapy and Comprehensive Disease Management

In renal cell carcinoma (RCC), continued advances in targeted therapy and immunotherapy have ushered patients with advanced disease into an era of long-term survival and chronic disease management. However, important clinical challenges remain, including optimizing adjuvant treatment for high-risk patients after surgery, selecting effective therapies following immunotherapy resistance, and developing multidisciplinary models for comprehensive care throughout the disease course.
CUDA 2026 | Prof. Nianzeng Xing: Advancing Urology Through Collaboration and Innovation

CUDA 2026 | Prof. Nianzeng Xing: Advancing Urology Through Collaboration and Innovation

The 2026 Annual Meeting of the Chinese Urological Association (CUDA) was held in Zhengzhou from June 11–14, 2026. As one of China's most influential national academic meetings in urology, this year's conference adopted the theme "Collaboration and Innovation", bringing together leading domestic and international experts to discuss advances in minimally invasive surgery, robotic technology, precision medicine, and multidisciplinary cancer care, while promoting high-quality specialty development and the translation of scientific advances into clinical practice.
19th CUA Genitourinary Oncology Conference | Professor Baojun Wang: Breaking Through the Bottlenecks in Prostate Cancer Treatment—Balancing Clinical Innovation with Standardized Care

19th CUA Genitourinary Oncology Conference | Professor Baojun Wang: Breaking Through the Bottlenecks in Prostate Cancer Treatment—Balancing Clinical Innovation with Standardized Care

The 19th Chinese Urological Association (CUA) Genitourinary Oncology Conference was held in Beijing on July 3–4, 2026, under the theme "Advancing Frontiers, Standardizing Care, and Driving Collaborative Innovation." The meeting brought together leading experts in urologic oncology from across China to examine the current challenges facing the field and explore future directions for clinical research and patient care.
19th CUA Genitourinary Oncology Conference | Professor Xuesong Li: Advancing the UTUC Subspecialty Through High-Quality Research to Address Key Clinical Challenges

19th CUA Genitourinary Oncology Conference | Professor Xuesong Li: Advancing the UTUC Subspecialty Through High-Quality Research to Address Key Clinical Challenges

The 19th Chinese Urological Association (CUA) Genitourinary Oncology Conference was held in Beijing on July 3–4, 2026, bringing together leading experts from across China under the theme "Advancing Frontiers, Standardizing Care, and Driving Collaborative Innovation." The meeting provided a platform for discussing new directions in urologic oncology research and clinical practice.
19th CUA Genitourinary Oncology Conference | Professor Kan Gong: Taking a Pragmatic View of AI in Clinical Practice While Building a China-Specific Evidence Base for Urologic Oncology

19th CUA Genitourinary Oncology Conference | Professor Kan Gong: Taking a Pragmatic View of AI in Clinical Practice While Building a China-Specific Evidence Base for Urologic Oncology

The 19th Chinese Urological Association (CUA) Genitourinary Oncology Conference was successfully held in Beijing on July 3–4, 2026. Centered on the theme "Advancing Frontiers, Standardizing Care, and Driving Collaborative Innovation," the meeting featured in-depth discussions on precision oncology, early screening and prevention of prostate cancer, and the development of a robust domestic clinical research ecosystem, highlighting both the latest advances and the key challenges facing urologic oncology in China.
Blood Advances Study | Director Zhihui Li’s Team Demonstrates Survival Benefit of HSCT in Advanced ENKTCL, Paving the Way for Precision Risk Stratification

Blood Advances Study | Director Zhihui Li’s Team Demonstrates Survival Benefit of HSCT in Advanced ENKTCL, Paving the Way for Precision Risk Stratification

Extranodal NK/T-cell lymphoma (ENKTCL) is a rare, highly aggressive lymphoid malignancy closely associated with Epstein–Barr virus (EBV) infection. Patients with advanced-stage or relapsed/refractory (R/R) disease continue to face poor outcomes, making effective treatment a longstanding clinical challenge. Recently, Director Zhihui Li and colleagues from Beijing GoBroad Boren Hospital published a study in Blood Advances entitled "HSCT May Improve Survival in Advanced Extranodal NK/T-Cell Lymphoma: A Single-Center Retrospective Study."
CSCO 10th Hematologic Malignancies Congress | Director Yajing Zhang: Moving Beyond “Target-Centric” Thinking to Redefine Lifelong Management of Hematologic Malignancies Through a Systems-Based Approach

CSCO 10th Hematologic Malignancies Congress | Director Yajing Zhang: Moving Beyond “Target-Centric” Thinking to Redefine Lifelong Management of Hematologic Malignancies Through a Systems-Based Approach

From July 10–12, 2026, the 10th Hematologic Malignancies Congress of the Chinese Society of Clinical Oncology (CSCO) was held in Harbin, China. Over the past decade, the meeting has grown into one of China's premier academic forums for hematologic oncology. This year's congress not only celebrated ten years of scientific achievement but also marked an important milestone for future innovation.